Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review

医学 观察研究 安慰剂 激素避孕 止痛 非甾体 临床试验 醋酸氯马地平 随机对照试验 盆腔疼痛 计划生育 妇科 人口 替代医学 内科学 外科 研究方法 病理 环境卫生
作者
Hans-Peter Zahradnik,A. Hanjalic-Beck,Klaus Groth
出处
期刊:Contraception [Elsevier]
卷期号:81 (3): 185-196 被引量:155
标识
DOI:10.1016/j.contraception.2009.09.014
摘要

This article is a comprehensive overview of dysmenorrhea and a systematic review of the available literature on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal contraceptives for the therapy and management of dysmenorrhea.A comprehensive search of the PubMed database for clinical trials and observational studies of dysmenorrhea treatments from 2004 onwards.Eighteen publications were identified. Ten randomized controlled trials (RCTs) assessing NSAIDs for treating primary dysmenorrhea demonstrated superior pain relief compared with placebo, but no superiority was established among different NSAIDS. Two RCTs and six nonrandomized observational or prospective studies assessing the effect of hormonal contraceptives on dysmenorrhea strongly suggest a beneficial effect for dysmenorrheic pain relief and were conducted mainly in larger populations (N=41-6169) than those in the NSAID trials (N=10-337). Ethinylestradiol/chlormadinone acetate was the only formulation that provided a more pronounced relief of dysmenorrheic pain compared with a parallel alternative or previously used hormonal contraceptive. Methodological inconsistencies were widespread between the hormonal contraceptive studies.The findings of this review support the use of NSAIDs as a first-line therapy for pain relief from dysmenorrhea in women without wish for contraception. For women who wish contraception, combined oral contraceptives (COCs) are the preferential therapy for pain relief from dysmenorrhea as the additional noncontraceptive benefit of pain relief from dysmenorrhea is not linked to additional risks, eliminates the risks associated with taking NSAIDs and is a more suitable long-term option. Recommendations are made to strengthen the impact of future trials through improved methodology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我爱科研完成签到 ,获得积分10
1秒前
执着夏山完成签到,获得积分10
2秒前
喜乐完成签到,获得积分20
5秒前
霍霍完成签到 ,获得积分10
6秒前
leaolf完成签到,获得积分10
6秒前
一三二五七完成签到 ,获得积分10
7秒前
ACMI完成签到,获得积分10
9秒前
完美世界应助不解释采纳,获得10
12秒前
LI完成签到,获得积分10
14秒前
白桃乌龙完成签到,获得积分10
16秒前
笨笨烨华完成签到 ,获得积分10
19秒前
Zyq1231完成签到,获得积分10
20秒前
哈哈完成签到 ,获得积分10
24秒前
飞龙在天完成签到,获得积分0
27秒前
轻松的雨竹完成签到 ,获得积分10
27秒前
28秒前
追寻奇迹完成签到 ,获得积分10
28秒前
在下常威完成签到,获得积分10
30秒前
NWP完成签到,获得积分10
36秒前
鳗鱼谷丝完成签到 ,获得积分10
37秒前
GuangboXia完成签到,获得积分10
39秒前
天天快乐应助科研通管家采纳,获得10
39秒前
李爱国应助科研通管家采纳,获得10
39秒前
深情安青应助科研通管家采纳,获得10
40秒前
科研通AI2S应助科研通管家采纳,获得10
40秒前
WonderHua应助科研通管家采纳,获得10
40秒前
guoguo应助科研通管家采纳,获得10
40秒前
alexlpb完成签到,获得积分10
40秒前
dream完成签到 ,获得积分10
40秒前
牛奶开水完成签到 ,获得积分10
43秒前
洁白的故人完成签到,获得积分10
43秒前
一只五条悟完成签到,获得积分10
45秒前
瀚子完成签到,获得积分10
48秒前
51秒前
123发布了新的文献求助10
57秒前
自由冬亦完成签到,获得积分10
1分钟前
gnr2000完成签到,获得积分0
1分钟前
831143完成签到 ,获得积分0
1分钟前
小超人完成签到 ,获得积分10
1分钟前
Yjh完成签到,获得积分10
1分钟前
高分求助中
Solution Manual for Strategic Compensation A Human Resource Management Approach 1200
Natural History of Mantodea 螳螂的自然史 1000
Glucuronolactone Market Outlook Report: Industry Size, Competition, Trends and Growth Opportunities by Region, YoY Forecasts from 2024 to 2031 800
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
Autoregulatory progressive resistance exercise: linear versus a velocity-based flexible model 500
The analysis and solution of partial differential equations 400
Sociocultural theory and the teaching of second languages 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3339148
求助须知:如何正确求助?哪些是违规求助? 2967059
关于积分的说明 8628100
捐赠科研通 2646545
什么是DOI,文献DOI怎么找? 1449297
科研通“疑难数据库(出版商)”最低求助积分说明 671343
邀请新用户注册赠送积分活动 660176